Send the following on WhatsApp
Continue to Chat信達生物宣佈Claudin18.2/CD3雙特異性抗體藥物IBI389完成首例臨床患者給藥 https://geneonline.news/t-cell-engager-tumor-associated-antigen/
信達生物宣佈Claudin18.2/CD3雙特異性抗體藥物IBI389完成首例臨床患者給藥 https://geneonline.news/t-cell-engager-tumor-associated-antigen/